Atara Biotherapeutics, Inc. (ATRA) Form 8-K — Jun 12, 2026
Atara Biotherapeutics appointed Brian Cherry as a new independent director and member of the Audit Committee, effective June 11, 2026. He received an initial award of 24,000 restricted stock units vesting over three years and an annual cash retainer of $55,000. The company also reported results from its 2026 annual meeting held on June 9, 2026. Shareholders elected nominees AnhCo Nguyen and Nachi Subramanian to the board, approved the executive compensation advisory vote, and ratified Deloitte & Touche LLP as the independent auditor.
Key figures
- Rsu award
- 24000
- Annual cash retainer
- 55000
- Votes for say on pay
- 3526411
- Votes against say on pay
- 44481
- Votes for director nguyen
- 3543113
- Votes for director subramanian
- 2581435
- Votes withheld director nguyen
- 32311
- Votes for equity plan amendment
- 3521021
- Votes against equity plan amendment
- 51327
- Votes withheld director subramanian
- 993989
- Shares reserved equity plan increase
- 400000
Price after filing
Close on the filing date to close N calendar days later (from $10.46). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.